XTX Topco Ltd Lowers Stock Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI)

XTX Topco Ltd lowered its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 16.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 13,485 shares of the company’s stock after selling 2,602 shares during the period. XTX Topco Ltd’s holdings in Denali Therapeutics were worth $183,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Price T Rowe Associates Inc. MD raised its holdings in shares of Denali Therapeutics by 6.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,058,615 shares of the company’s stock valued at $62,335,000 after buying an additional 188,820 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Denali Therapeutics by 19.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,855,036 shares of the company’s stock worth $37,805,000 after acquiring an additional 295,594 shares in the last quarter. Northern Trust Corp lifted its holdings in shares of Denali Therapeutics by 10.7% in the 4th quarter. Northern Trust Corp now owns 1,201,518 shares of the company’s stock worth $24,487,000 after acquiring an additional 115,876 shares during the last quarter. Stempoint Capital LP boosted its stake in shares of Denali Therapeutics by 107.2% in the 4th quarter. Stempoint Capital LP now owns 584,328 shares of the company’s stock valued at $11,909,000 after purchasing an additional 302,278 shares in the last quarter. Finally, Polar Asset Management Partners Inc. grew its holdings in shares of Denali Therapeutics by 1,240.9% during the 4th quarter. Polar Asset Management Partners Inc. now owns 551,092 shares of the company’s stock valued at $11,231,000 after purchasing an additional 509,992 shares during the last quarter. 92.92% of the stock is currently owned by hedge funds and other institutional investors.

Denali Therapeutics Price Performance

Shares of DNLI stock opened at $14.81 on Thursday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.56 and a current ratio of 10.27. Denali Therapeutics Inc. has a fifty-two week low of $10.57 and a fifty-two week high of $33.33. The firm has a market cap of $2.17 billion, a P/E ratio of -5.29 and a beta of 1.36. The business’s 50 day moving average price is $14.29 and its 200-day moving average price is $15.48.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.72) EPS for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.02. During the same period in the previous year, the business posted ($0.59) earnings per share. On average, equities research analysts anticipate that Denali Therapeutics Inc. will post -2.71 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Ryan J. Watts sold 495,282 shares of Denali Therapeutics stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $15.00, for a total transaction of $7,429,230.00. Following the sale, the chief executive officer owned 253,071 shares of the company’s stock, valued at approximately $3,796,065. The trade was a 66.18% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 12.50% of the company’s stock.

Analyst Upgrades and Downgrades

DNLI has been the topic of a number of analyst reports. Wedbush decreased their target price on shares of Denali Therapeutics from $32.00 to $30.00 and set an “outperform” rating on the stock in a research report on Wednesday, May 7th. Bank of America decreased their price objective on Denali Therapeutics from $28.00 to $27.00 and set a “buy” rating on the stock in a report on Monday, May 19th. TD Cowen raised Denali Therapeutics to a “strong-buy” rating in a research note on Monday, July 28th. HC Wainwright dropped their target price on Denali Therapeutics from $80.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, May 7th. Finally, William Blair raised Denali Therapeutics to a “strong-buy” rating in a research note on Thursday, April 24th. One analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $33.85.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.